TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05859477
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine 1000 mg/m², orally, twice a day, days 1-14 of each cycle
Study: NCT05283850
Drug: High Calcium, Low Sodium (HCLS) Crystalloid Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-normal saline IV drip and 1g IV bolus Calcium Chloride.
Study: NCT05283850
Drug: High Calcium, High Sodium (HCHS) Crystalloid Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline IV drip and 1g IV bolus Calcium Chloride.
Study: NCT05067270
Drug: Humalog diluent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC infusion.
Study: NCT05522439
Drug: SHR-1703 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo will be administered by the SC route.
Study: NCT04453293
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vaccine diluent, 0.1 mL given as single dose by intradermal injection over the outer lower aspect of the deltoid region
Study: NCT05970016
Drug: TCC1727 tablet（1）
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCC1727 tablet will be administered orally once a day (QD) every morning for 3 days followed by discontinuation for 4 days, and 21 days/cycle on an empty stomach.
Study: NCT05970016
Drug: TCC1727 tablet（2）
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: TCC1727 tablet TCC1727 tablet will be administered orally twice a day (BID) every morning , and 21 days/cycle on an empty stomach.
Study: NCT06005610
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 17-β estradiol 2 mg once daily will be initiated at study entry. At weeks 4, 12, 24, and 36, study clinicians may titrate 17-β estradiol in 2 mg increments to achieve the desired participant goals and target hormone concentrations, as measured locally at each visit.
Study: NCT06232434
Drug: Prospidelong
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prospidium chloride (in the form of prospidelong (a mixture of prospidium chloride and dextran sodium salt phosphate containing carbamate groups in a 1:1 ratio)) - 1000 mg.
Study: NCT05125237
Drug: Amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amiloride claim is used as the exposure group.
Study: NCT06330038
Drug: Inhaled anesthetics
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled anesthetics will be used for the maintenance of general anesthesia.
Study: NCT05832281
Drug: Purysis CBD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Purysis, or synthetic CBD, which will be compared to placebo
Study: NCT05832281
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Purysis
Study: NCT06561672
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous injection of 1.5 microgram/kg fentanyl will be given to the patient followed by induction agents (propofol 2mg/kg).
Study: NCT04061421
Drug: ASTX727
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken by mouth daily during days 1-5 of every 28-day cycle.
Study: NCT06342830
Drug: Ciprofloxacin 500 mg +ibuprofen 400mg
Normalized name: ciprofloxacin 500 MG
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: firstly patient anesthetized, rubber dam isolation , disinfect the crown with 10%H2O2, saline then sodium hypochlorite solution 2.5% then 5% sodium thiosulphate solution to inhibit the effect of NaOHCl then removal of old coronal restoration, disinfection of pulp chamber by the same previous protocol removal of old root canal filling with gates glidden drills and H files , taken first sample S1 from canal with paper point after using saline wash and scrubbing the canal wall the paper points left for 1 min in the canal then preparation of canal with edge endo files till size 45 taper 0.4 and NaOHCL 2.5 % between each file and the next finally 5% sodium thiosulphate to inhibit the antibacterial effect of sodium hypochlorite irrigation then saline irrigation and scrubbing the canal wall and placement of paper points for 1min to taken second sample S2, then dryness of canal and placement of ciprofloxacin + ibuprofen gel until fill the canal under magnification and by using lentulospirals
Study: NCT05275907
Drug: Chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg capsule once daily for 6 weeks
Study: NCT05361772
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 0.5mg per day for 24 months
Study: NCT06342830
Drug: Metapaste [calcium hydroxide paste (control group)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: firstly patient anesthetized, rubber dam isolation , disinfect the crown with 10%H2O2, saline then sodium hypochlorite solution 2.5% then 5% sodium thiosulphate solution to inhibit the effect of NaOHCl then removal of old coronal restoration, disinfection of pulp chamber by the same previous protocol removal of old root canal filling with gates glidden drills and H files , taken first sample S1 from canal with paper point after using saline wash and scrubbing the canal wall the paper points left for 1 min in the canal then preparation of canal with edge endo files till size 45 taper 0.4 and NaOHCL 2.5 % between each file and the next finally 5% sodium thiosulphate to inhibit the antibacterial effect of sodium hypochlorite irrigation then saline irrigation and scrubbing the canal wall and placement of paper points for 1min to taken second sample S2, then dryness of canal and placement of calcium hydroxide paste until fill the canal under magnification by using lentulospirals
Study: NCT06154837
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered.
Study: NCT06653322
Drug: HR-1703
Normalized name: Synovex H
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR-1703 will be administered by SC injection.
Study: NCT06653322
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo will be administered by the SC injection.
Study: NCT06488924
Drug: JR-446
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT05573204
Drug: Obeticholic Acid Oral Tablet
Normalized name: obeticholic acid Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obeticholic acid used as 10 mg tablet once daily for 6 months
Study: NCT04629339
Drug: INCB086550
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB086550 will be administered orally twice a day.
Study: NCT06048588
Drug: Placebo for YN001
Approvals — FDA: no, EMA: no, PMDA: no
Description: The injection solution to mimic the YN001
Study: NCT06048588
Drug: rosuvastatin calcium tablets
Normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In MAD part of study in patients with coronary atherosclerosis, Rosuvastatin calcium tablets will be taken orally by 10 mg daily up to 85 days
Study: NCT03999216
Drug: Loop Diuretics vs. loop + thiazide diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive the diuretic type as determined by the randomized group assignment starting within the first 24 hours of hospital admission and continuing for up to 72 hours. All other treatments are left to the discretion of the treatment team, as this is a pragmatic randomized trial.
Study: NCT04788979
Drug: Melatonin 5Mg Oral Tablet
Normalized name: Melatonin 5mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. control without treatment~2. obese periodontitis patients treated only by scaling and root planning~3. obese periodontitis patients treated with scaling and root planning with daily dietary supplementation of 5 mg melatonin (NOW-USA)
Study: NCT05195008
Drug: BIIB113-Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT05195008
Drug: 11^C]BIO-1819578
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT06110130
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take Placebo 10 mg orally daily for 4 months
Study: NCT04951986
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo identical to Prednisone
Study: NCT06151561
Drug: AGN-151586
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Injection
Study: NCT06151561
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Injection
Study: NCT05698680
Drug: Prednisolone 30 mg Tablet
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See treatment arm Prednisolone
Study: NCT05125224
Drug: Dihydropyridine calcium channel blocker
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydropyridine calcium channel blocker claim is used as the exposure group.
Study: NCT05493735
Drug: Placebo Jelly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the control arm will undergo pessary removal and reinsertion after the application of lubricating jelly.
Study: NCT06301880
Drug: The topical application of a vasodilator on the LIMA graft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were randomly assigned to receive the topical application of one of three agents: milrinone (Baxter Pharmaceuticals, Ahmedabad, India) 10 mg in 20 ml of dextrose 5%, nitroglycerin (Caspian Tamin Pharmaceutical, Guilan, Iran) 10 mg in 20 ml of normal saline, or normal saline (0.9% sodium chloride solution) as control.
Study: NCT06302218
Drug: control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: only spinal anesthesia
Study: NCT05564169
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment per os
Study: NCT05564169
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitors (donepezil, rivastigmine or galantamine) and/or memantine
Study: NCT05947383
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin 100 mg oral capsule
Study: NCT04904562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05664087
Drug: Dental diode laser device Paiwei™（Zhengzhou Gata biotechnology Co.,Ltd.,China） which was 650-670nm with a power of 160mw-220mw.
Approvals — FDA: no, EMA: no, PMDA: no
Description: The tooth extraction sockets were filled with photosensitizer methylene blue. The guide head of the laser periodontal therapy instrument (Dental diode laser device Paiwei™（Zhengzhou Gata biotechnology Co.,Ltd.,China） which was 650-670nm with a power of 160mw-220mw.) was placed in the tooth extraction sockets to probe and move around the tooth extraction sockets for 1 minute. At the end of irradiation, a cotton ball dipped in saline was used to wipe the guide head and rinse the photosensitizer out of the socket
Study: NCT06561763
Drug: Nimotuzumab,Toripalimab，Cisplatin, albumin paclitaxel, capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin paclitaxel 200g/m2, intravenous drip administration, d1; Cisplatin 60 mg/m2， Intravenous , d1; Capecitabine, 1000mg/m2, orally administered D1-14； Triprolizumab injection 240mg, intravenous D1; Nivolumab 400mg, intravenous D1; Q3W 1 cycle, 3 cycles Period, 3 weeks in total
Study: NCT06561594
Drug: recombinant human follicle-stimulating hormone-CTP Fusion protein injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IF Weight \> 60kg，150ug, H. Administer the drug once every 14 days for 64 weeks；IF Weight \>≤60kg，100ug, H. Administer the drug once every 14 days for 64 weeks
Study: NCT06561594
Drug: recombinant human follicle-stimulating hormone-CTP Fusion protein injection Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5ml, H. Administer the drug once every 14 days for 64 weeks
Study: NCT05456425
Drug: CBT-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT-001 eye drop
Study: NCT05456425
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation without drug
Study: NCT05156827
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline administered through IV infusion over an hour
Study: NCT05875259
Drug: BR1019-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group B : One tablet of BR1019-2 administered alone once daily for 7 days.
Study: NCT05875259
Drug: BR1019-1 + BR1019-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group C : One tablet each of BR1019-1 and BR1019-2 administered in combination once daily for 7 days.
Study: NCT04807348
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of Chiglitazar
Study: NCT05412576
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable
Study: NCT05374057
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: See study arm.
Study: NCT06227377
Drug: QTX3034
Approvals — FDA: no, EMA: no, PMDA: no
Description: QTX3034 will be administered at protocol defined dose
Study: NCT06164379
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At every visit, the clinic and ambulatory blood pressure will be measured. The levels of serum potassium, creatinine, renin, aldosterone will be examined. The urinary microalbumin creatinine ratio will be also examined.
Study: NCT06044493
Drug: Myreptic-N Tablet
Normalized name: N-ethylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 720mg BID(total 1440mg daily), PO - Check the blood concentration of Mycophenolate at each visit
Study: NCT06044493
Drug: Mycophenolate mofetil Tablet/Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 1g BID(total 2g daily), PO - Check the blood concentration of Mycophenolate at each visit
Study: NCT04354129
Drug: Cutaquig®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoglobulin replacement therapy with subcutaneous injections of Cutaquig® 165 mg/mL at home.
Study: NCT06085716
Drug: Open Label Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will only take placebo capsules every day.
Study: NCT06585696
Drug: CU-20101 treatment for Moderate to Severe Glabellar Striae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part I (randomized double-blind controlled study) Study Part 1 consisted of a 1-day baseline/treatment period (randomized and received 1 dose of study treatment) and a 12-week post-treatment follow-up period.~Part II (open-label study) For subjects who completed Part I of the study, they automatically entered Period 2 of the study. To evaluate the safety, efficacy, and immunogenicity of repeated injections of CU-20101 in the treatment of moderate to severe glabellar striae if they meet the criteria for repeat treatment (as shown in Figure 1, at least 12 weeks apart from each test drug injection). If repeat treatment criteria are not met at follow-up, follow-up may continue after 4 weeks until the next treatment is met. The last study treatment was no later than Day 253 ± 7 days (Week 36).
Study: NCT06648655
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily (QD) x 14 weeks.
Study: NCT06564207
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to be given twice daily for 14 days
Study: NCT05619627
Drug: General Anesthesia (control group)
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive general anesthesia for their MRI
Study: NCT04131803
Drug: Bifico combined with chemotherapy plus targeted therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifico combined with chemotherapy plus targeted therapy
Study: NCT04131803
Drug: chemotherapy plus targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy plus targeted therapy
Study: NCT05976646
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects who are randomized to placebo will receive identical capsules to the test product at the same time periods noted above, administered orally.
Study: NCT05712187
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet BID
Study: NCT06221475
Drug: BAY2927088 coated tablet 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 coated tablets (10 mg) per single dose 30 min after a light meal
Study: NCT06221475
Drug: [14C]-BAY2927088 solution for infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion 15 min ending at 2 hours oral post-dose
Study: NCT05672342
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05712044
Drug: Folic Acid 5 MG
Normalized name: folic acid 5 MG
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 5mg tablets will be administered orally every 8 hours then samples from buccal mucosa will be taken 15 days and 30 days after suplementation.
Study: NCT05738850
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT05438316
Drug: Tritace® tablet 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tritace® is manufactured by Sanofi-Aventis Deutschland GmbH, Germany. Each tablet contains 10 mg of ramipril.
Study: NCT03678480
Drug: HTD1801
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTD1801 capsules, 250mg
Study: NCT05133440
Drug: Radium dichloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two cycles of Radium (Ra-223) dichloride at 55 kBq/kg or 0.00149 mCi/kg or 1.49 uCi/kg every 4 weeks followed 2-3 weeks later by SBRT at a dose of 9 Gy per fraction for 3 fractions (total dose of 27 Gy) to all sites of radiographically apparent metastatic disease. SBRT fractions can be administered every day or every other day per institutional practice. An additional 4 cycles of Radium (Ra-223) dichloride at 55 kBq/kg or 0.00149 mCi/kg or 1.49 uCi/kg every 4 weeks will then be administered, resuming 2-3 weeks after completion of the final fraction of SBRT.
Study: NCT04842201
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection
Study: NCT05209984
Drug: SIB Group Sibus (Sibutramine) 15mg
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant will receive for two (02) weeks one (01) 10mg sibutramine placebo capsule + one (01) 5mg/25mg sibutramine ADF placebo capsule IR/topiramate XR; after this initial period, they will receive for two (02) weeks one (01) 10mg sibutramine capsule + two (02) placebo capsules of ADF sibutramine IR/topiramate XR 5mg/25mg; after this 4-week period, participants will receive one (01) 10mg sibutramine capsule and three (03) ADF sibutramine IR/topiramate XR 5mg/25mg placebo capsules, taken once daily, for two (02) additional weeks. This corresponds to the titration scheme.On the treatment period, patient will receive one (01) Sibutramine 15mg capsule + one (01) Sibutramine IR/topiramate XR 15mg/75mg placebo capsule + one (01) placebo capsule of Topiramate XR 100mg, taken once daily, for 52 weeks.
Study: NCT06561035
Drug: Opiate Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive medications in the Opiate Based arm for pain control.
Study: NCT05209984
Drug: Placebo Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: participants randomized to the Placebo Group will receive for two (02) weeks one (01) 10mg sibutramine placebo capsule + one (01) sibutramine IR/ topiramate XR 5mg/25mg placebo capsule; after this initial period, they will receive one (01) sibutramine 10mg placebo capsule + two (02) sibutramine IR/ topiramate XR 5mg/25mg placebo capsules, taken once daily, for two (02) weeks; after this 4-week period, participants will receive one (01) 10mg sibutramine placebo capsule + three (03) ADF placebo capsules, taken once daily, for two (02) weeks.On the treatment period, patient will receive one (01) Sibutramine 15mg placebo capsule + one (01) ADF sibutramine IR/Topiramate XR 15mg/75mg placebo capsule + one (01) Topiramate XR 100mg placebo capsule, in once daily intake for 52 weeks.
Study: NCT05538572
Drug: PRT3645
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRT3645 capsules will be self-administered once daily, continuously, at the dose-level assigned
Study: NCT04730206
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets, identical in size and shape
Study: NCT05667324
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single injection into the pterygopalatine fossa bilaterally of a balanced crystalloid intravenous solution (4 ml of normal saline)
Study: NCT05726253
Drug: Supportive Care + Placebo (no antibiotics)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to receive oral placebo for a standard course (7 days)
Study: NCT05025085
Drug: AGEN1777
Approvals — FDA: no, EMA: no, PMDA: no
Description: An immunoglobulin gamma (IgG1) antibody
Study: NCT04880577
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo arm
Study: NCT05286060
Drug: GX-188E, GX-I7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug 1: GX-188E GX-188E, 2mg (1.0mg/0.5ml/vial), Intramuscular administration using electroporator Other Name: Tirvalimogene teraplasmid Drug 2: GX-I7 GX-I7 360㎍/kg, intramuscular administration Other Name: NT-I7, rhIL-7-hyFc, efineptakin alfa
Study: NCT05580029
Drug: EMLA 5% cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/10cm2 Topical 30 minutes before each fractional ablative CO2 session
Study: NCT05125211
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administrated oral spray
Study: NCT04797663
Drug: TCA 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemical peel
Study: NCT05409547
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-rhG-CSF 6 mg/d (single dose) will be given on the second day after chemotherapy.
Study: NCT05393050
Drug: Methotrexate tablets
Normalized name: Methotrexate Tablets
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate is a drug used to treat rheumatoid arthritis
Study: NCT06479655
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl infusion with dilution of 10mcg/ml
Study: NCT06165354
Drug: 0.9% NaCl physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal-spraying 0.9% NaCl physiological saline is prepared by extracting 10 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque metallic spraying 20 mL-bottle.